(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced that a comprehensive summary of clinical trials evaluating HyBryte(TM) (synthetic hypericin) for ...
PHILADELPHIA and VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ...
BioNTech will present significant clinical trial data at the prestigious ASCO Annual Meeting, highlighting the advancement of its diversified oncology portfolio. The preliminary results for BNT327 and ...
Cabaletta Bio, Inc. announced promising clinical data regarding its investigational therapy, resecabtagene autoleucel (rese-cel), for autoimmune diseases during recent scientific meetings. Among the ...
PLYMOUTH, Mass.--(BUSINESS WIRE)--IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies, today announced updated ...
33% Response Rate and 100% Disease Control Rate Observed in Patients Evaluated for Efficacy Complete Response of Non-Target Tumor Also Observed Platinum-Resistant Ovarian Cancer is a Devastating ...
Application of a Data Quality Framework to Ductal Carcinoma In Situ Using Electronic Health Record Data From the All of Us Research Program The availability and timing of clinician assessments was ...
Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"
(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results